AstraZeneca plc (LON:AZN) had its price objective raised by HSBC Holdings plc from GBX 4,150 ($54.58) to GBX 4,340 ($57.08) in a research report report published on Wednesday, November 1st. The brokerage currently has a reduce rating on the biopharmaceutical company’s stock.
A number of other equities analysts have also weighed in on the stock. Citigroup Inc. reiterated a buy rating and issued a GBX 6,000 ($78.92) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Barclays PLC set a GBX 6,300 ($82.86) target price on shares of AstraZeneca plc and gave the stock a buy rating in a research report on Wednesday, September 13th. Goldman Sachs Group, Inc. (The) restated a sell rating and set a GBX 3,800 ($49.98) target price on shares of AstraZeneca plc in a research report on Tuesday, October 17th. Liberum Capital restated a buy rating and set a GBX 4,800 ($63.13) target price on shares of AstraZeneca plc in a research report on Tuesday, September 5th. Finally, Natixis upgraded shares of AstraZeneca plc from a neutral rating to a buy rating and increased their price objective for the company from GBX 5,000 ($65.76) to GBX 5,738 ($75.47) in a research report on Wednesday, September 6th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of GBX 5,247.18 ($69.01).
Shares of AstraZeneca plc (AZN) opened at GBX 4,870 ($64.05) on Wednesday. AstraZeneca plc has a twelve month low of GBX 3,996 ($52.56) and a twelve month high of GBX 5,520 ($72.60).
COPYRIGHT VIOLATION WARNING: “AstraZeneca plc (AZN) Price Target Increased to GBX 4,340 by Analysts at HSBC Holdings plc” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/12/astrazeneca-plc-azn-pt-raised-to-gbx-4340.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.